Stockholders Approve 27% Potential Dilution from Expanded Equity Incentive Plan
Summary
Hepion Pharmaceuticals' stockholders approved a major expansion of its equity incentive plan, increasing the share pool by 7.8 million shares, which could lead to approximately 27% dilution for existing shareholders.
Key Events
-
Equity Incentive Plan Expanded
Stockholders approved an amendment to the 2023 Omnibus Equity Incentive Plan, increasing the number of shares issuable thereunder from 200,000 to 8,000,000.
-
Significant Potential Dilution
The increase of 7.8 million shares represents a potential dilution of approximately 26.79% based on the 29,119,476 shares outstanding as of the record date.
-
Director Re-elections Confirmed
Five directors, including Interim CEO Gary Stetz and Executive Chairman Vincent LoPriore, were re-elected to the board.
Analysis
Hepion Pharmaceuticals' stockholders approved a significant expansion of its 2023 Omnibus Equity Incentive Plan, increasing the share pool by 7.8 million shares. This authorization introduces substantial potential dilution for existing shareholders, representing approximately 27% of current outstanding shares. The approval comes as the company faces a "going concern" warning, highlighting the critical need to incentivize management and employees, but at a considerable potential cost to shareholder value. This formalizes a proposal previously outlined in a DEFA14A filing on April 28, 2026.
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.